1. Home
  2. ANIP vs KYN Comparison

ANIP vs KYN Comparison

Compare ANIP & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANIP
  • KYN
  • Stock Information
  • Founded
  • ANIP 2001
  • KYN 2004
  • Country
  • ANIP United States
  • KYN United States
  • Employees
  • ANIP N/A
  • KYN N/A
  • Industry
  • ANIP Biotechnology: Pharmaceutical Preparations
  • KYN Finance/Investors Services
  • Sector
  • ANIP Health Care
  • KYN Finance
  • Exchange
  • ANIP Nasdaq
  • KYN Nasdaq
  • Market Cap
  • ANIP 2.0B
  • KYN 2.1B
  • IPO Year
  • ANIP N/A
  • KYN N/A
  • Fundamental
  • Price
  • ANIP $95.75
  • KYN $12.35
  • Analyst Decision
  • ANIP Strong Buy
  • KYN
  • Analyst Count
  • ANIP 9
  • KYN 0
  • Target Price
  • ANIP $89.11
  • KYN N/A
  • AVG Volume (30 Days)
  • ANIP 394.4K
  • KYN 561.5K
  • Earning Date
  • ANIP 11-07-2025
  • KYN 01-01-0001
  • Dividend Yield
  • ANIP N/A
  • KYN 8.99%
  • EPS Growth
  • ANIP N/A
  • KYN N/A
  • EPS
  • ANIP N/A
  • KYN 0.71
  • Revenue
  • ANIP $747,399,000.00
  • KYN N/A
  • Revenue This Year
  • ANIP $39.36
  • KYN N/A
  • Revenue Next Year
  • ANIP $9.45
  • KYN N/A
  • P/E Ratio
  • ANIP N/A
  • KYN $13.79
  • Revenue Growth
  • ANIP 38.68
  • KYN N/A
  • 52 Week Low
  • ANIP $52.50
  • KYN $7.84
  • 52 Week High
  • ANIP $99.50
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • ANIP 63.57
  • KYN 54.15
  • Support Level
  • ANIP $95.11
  • KYN $12.09
  • Resistance Level
  • ANIP $99.39
  • KYN $12.29
  • Average True Range (ATR)
  • ANIP 2.27
  • KYN 0.16
  • MACD
  • ANIP -0.89
  • KYN 0.01
  • Stochastic Oscillator
  • ANIP 50.13
  • KYN 44.83

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: